GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Pre-Tax Income

HALB (Halberd) Pre-Tax Income : $ Mil (TTM As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Halberd's pretax income for the six months ended in Jul. 2023 was $-0.45 Mil. Halberd does not have enough years/quarters to calculate the pretax income for the trailing twelve months (TTM) ended in Jul. 2023. Halberd's pretax margin was -15,133.33%.

During the past 3 years, Halberd's highest Pretax Margin was -757.14%. The lowest was -20312.50%. And the median was -15133.33%.


Halberd Pre-Tax Income Historical Data

The historical data trend for Halberd's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Pre-Tax Income Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Pre-Tax Income
-0.05 -1.63 -0.45

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Pre-Tax Income -0.05 -1.63 -0.45

Competitive Comparison of Halberd's Pre-Tax Income

For the Biotechnology subindustry, Halberd's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halberd's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Halberd's Pre-Tax Income falls into.


;
;

Halberd Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Halberd's Pretax Income for the fiscal year that ended in Jul. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.447+0+-0.007+0+0
=-0.45

Halberd's Pretax Income for the quarter that ended in Jul. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.447+0+-0.007+0+0
=-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd  (OTCPK:HALB) Pre-Tax Income Explanation

Halberd's Pretax Margin for the quarter that ended in Jul. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.454/0.003
=-15,133.33%

During the past 3 years, Halberd's highest Pretax Margin was -757.14%. The lowest was -20312.50%. And the median was -15133.33%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Halberd's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236